Disc Medicine (NASDAQ:IRON) COO Jonathan Yen-Wen Yu Sells 9,700 Shares of Stock

Disc Medicine, Inc. (NASDAQ:IRON) COO Jonathan Yen-Wen Yu sold 9,700 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $72.66, for a total value of $704,802.00. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at $3,947,181.84. This represents a 15.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jonathan Yen-Wen Yu also recently made the following trade(s):

• On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total value of $1,287,764.28.

Disc Medicine Trading Up 0.0%

NASDAQ IRON opened at $70.47 on Thursday. The firm has a market capitalization of $2.69 billion, a PE ratio of -10.64 and a beta of 0.93. The stock’s 50 day moving average is $68.80 and its 200 day moving average is $71.18. Disc Medicine, Inc. has a twelve month low of $40.00 and a twelve month high of $99.50. The company has a quick ratio of 24.00, a current ratio of 24.00 and a debt-to-equity ratio of 0.04.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by ($0.03). Research analysts forecast that Disc Medicine, Inc. will post -6.74 earnings per share for the current fiscal year.

Institutional Trading of Disc Medicine

Several institutional investors have recently added to or reduced their stakes in the business. Arizona State Retirement System raised its stake in shares of Disc Medicine by 2.2% in the fourth quarter. Arizona State Retirement System now owns 6,798 shares of the company’s stock worth $540,000 after purchasing an additional 144 shares during the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of Disc Medicine by 3.3% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,716 shares of the company’s stock valued at $533,000 after purchasing an additional 215 shares in the last quarter. AlphaCentric Advisors LLC boosted its position in shares of Disc Medicine by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 3,972 shares of the company’s stock valued at $254,000 after buying an additional 216 shares during the last quarter. Avanza Fonder AB boosted its position in shares of Disc Medicine by 14.1% during the fourth quarter. Avanza Fonder AB now owns 1,903 shares of the company’s stock valued at $151,000 after buying an additional 235 shares during the last quarter. Finally, Kennedy Capital Management LLC increased its holdings in Disc Medicine by 3.3% in the 4th quarter. Kennedy Capital Management LLC now owns 9,324 shares of the company’s stock worth $740,000 after buying an additional 296 shares in the last quarter. 83.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IRON has been the subject of a number of recent research reports. Truist Financial lowered their price target on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Wall Street Zen upgraded shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, April 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Monday, April 20th. Wedbush reiterated an “outperform” rating and set a $88.00 target price on shares of Disc Medicine in a report on Wednesday, June 10th. Finally, Wells Fargo & Company boosted their price target on Disc Medicine from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $105.80.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.